JP2024533067A5 - - Google Patents

Info

Publication number
JP2024533067A5
JP2024533067A5 JP2024512096A JP2024512096A JP2024533067A5 JP 2024533067 A5 JP2024533067 A5 JP 2024533067A5 JP 2024512096 A JP2024512096 A JP 2024512096A JP 2024512096 A JP2024512096 A JP 2024512096A JP 2024533067 A5 JP2024533067 A5 JP 2024533067A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
seq
composition according
activated anti
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024512096A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024533067A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2022/075608 external-priority patent/WO2023041622A1/en
Publication of JP2024533067A publication Critical patent/JP2024533067A/ja
Publication of JP2024533067A5 publication Critical patent/JP2024533067A5/ja
Pending legal-status Critical Current

Links

JP2024512096A 2021-09-15 2022-09-15 抗btn3a治療に対するレスポンダーの選択 Pending JP2024533067A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21306272 2021-09-15
EP21306272.2 2021-09-15
PCT/EP2022/075608 WO2023041622A1 (en) 2021-09-15 2022-09-15 Selection of responders for anti-btn3a treatment

Publications (2)

Publication Number Publication Date
JP2024533067A JP2024533067A (ja) 2024-09-12
JP2024533067A5 true JP2024533067A5 (cg-RX-API-DMAC7.html) 2025-09-24

Family

ID=77998935

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024512096A Pending JP2024533067A (ja) 2021-09-15 2022-09-15 抗btn3a治療に対するレスポンダーの選択

Country Status (6)

Country Link
US (1) US20230227558A1 (cg-RX-API-DMAC7.html)
EP (1) EP4401837A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024533067A (cg-RX-API-DMAC7.html)
CN (1) CN118475611A (cg-RX-API-DMAC7.html)
TW (1) TW202313695A (cg-RX-API-DMAC7.html)
WO (1) WO2023041622A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3830119T3 (pl) * 2018-08-01 2026-05-25 Imcheck Therapeutics Przeciwciała anty-btn3a i ich zastosowanie w leczeniu nowotworów albo zaburzeń zakaźnych
JP2026506893A (ja) * 2023-02-23 2026-02-27 イムチェック セラピューティクス エスエーエス Btn3a活性化抗体と免役チェックポイント阻害剤の併用
TW202506731A (zh) * 2023-04-27 2025-02-16 法商感應檢查療法公司 治療多重抗藥性細菌感染之方法
WO2024251981A1 (en) * 2023-06-09 2024-12-12 Umc Utrecht Holding B.V. Detecting and/or modulating susceptibility to btn2a1 and/or btn3a1 targeting therapeutics
WO2024261239A1 (en) * 2023-06-23 2024-12-26 Imcheck Therapeutics Bispecific antibodies targeting btn3a and the pd-1/pd-l1 inhibitory axis

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI903489A7 (fi) 1988-11-11 1990-07-10 Medical Res Council Yhden osan sisältävät ligandit, näitä ligandeja sisältävät reseptorit, menetelmiä niiden valmistamiseksi sekä ligandien ja reseptorien käytt ö
WO2012080769A1 (en) 2010-12-15 2012-06-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-cd277 antibodies and uses thereof
PL3830119T3 (pl) 2018-08-01 2026-05-25 Imcheck Therapeutics Przeciwciała anty-btn3a i ich zastosowanie w leczeniu nowotworów albo zaburzeń zakaźnych

Similar Documents

Publication Publication Date Title
JP2024037894A5 (cg-RX-API-DMAC7.html)
JP2022511394A5 (cg-RX-API-DMAC7.html)
RU2018146886A (ru) Пути терапевтического применения ингибитора c-raf
JP2020019787A5 (cg-RX-API-DMAC7.html)
JP2022510964A5 (cg-RX-API-DMAC7.html)
JP2020182492A5 (cg-RX-API-DMAC7.html)
JP2021528423A5 (cg-RX-API-DMAC7.html)
JP2024520666A5 (cg-RX-API-DMAC7.html)
JP2018534933A5 (cg-RX-API-DMAC7.html)
JP2022116269A5 (cg-RX-API-DMAC7.html)
JP2019519499A5 (cg-RX-API-DMAC7.html)
HRP20230517T1 (hr) Kombinacija anti-pd-1 antitijela i radijacijske terapije za liječenje raka
JP2020508317A5 (cg-RX-API-DMAC7.html)
FI3740504T3 (fi) CD70-yhdistelmähoito
JP2022515077A5 (cg-RX-API-DMAC7.html)
JP2017510559A5 (cg-RX-API-DMAC7.html)
RU2017132432A (ru) Конъюгаты антитело-лекарственное средство (adc), которые связываются с белками flt3
JP2017514795A5 (cg-RX-API-DMAC7.html)
JP2017514461A5 (cg-RX-API-DMAC7.html)
JP2022512851A5 (cg-RX-API-DMAC7.html)
WO2005044307A3 (en) Methods of therapy for b cell-related cancers
CN108079292A (zh) 一种抗pd-1抗体在制备治疗肝癌的药物中的用途
JP2023545084A5 (cg-RX-API-DMAC7.html)
JP2019524820A5 (cg-RX-API-DMAC7.html)
JP2023502398A5 (cg-RX-API-DMAC7.html)